Physician profile
James M Smith
NPI 1053395129
$4,754.89
in general payments reported to CMS, 2019-2025
34 companies · $968 in 2025
The $968 reported for 2025 was more than what 95% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $568 · 2020: $311 · 2021: $150 · 2022: $582 · 2023: $940 · 2024: $1,236 · 2025: $968.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,144.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,144.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $529.65 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $485.05 | 2022-2025 | Mounjaro, Trulicity, Zepbound |
| Astrazeneca Pharmaceuticals LP | $474.73 | 2020-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $371.46 | 2019-2025 | Ubrelvy, Qulipta, Vraylar |
| Astellas Pharma US INC | $349.72 | 2019-2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $327.99 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Glaxosmithkline, LLC. | $322.37 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Sanofi-Aventis U.S. LLC | $266.82 | 2019-2025 | |
| Pfizer INC. | $215.56 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $207.68 | 2019-2025 | Spravato |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $175.40 | 2021-2025 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $173.86 | 2019-2024 | |
| Amgen INC. | $84.69 | 2019-2024 | Otezla, Repatha |
| Dexcom, INC. | $81.52 | 2022-2024 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $70.44 | 2023-2024 | Gvoke Hypopen |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $69.94 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Otsuka America Pharmaceutical, INC. | $68.37 | 2023-2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $65.83 | 2022-2025 | |
| Inspire Medical Systems, INC. | $63.17 | 2025 | Inspire |
| Sumitomo Pharma America, INC. | $58.48 | 2024-2025 | Gemtesa |
| Shield Therapeutics INC | $45.97 | 2024 | |
| Edwards Lifesciences Corporation | $28.75 | 2025 | Sapien 3 Ultra Resilia |
| Merck Sharp & Dohme LLC | $26.75 | 2019 | |
| Axsome Therapeutics, INC. | $21.40 | 2025 | Auvelity |
| Radius Health, INC. | $19.84 | 2021 | |
| Antares Pharma, INC. | $19.11 | 2021 | |
| Eisai INC. | $18.72 | 2020 | |
| Amneal Pharmaceuticals LLC | $17.86 | 2025 | Crexont |
| Kowa Pharmaceuticals America, INC. | $17.53 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.35 | 2020 | |
| Amarin Pharma, INC. | $16.76 | 2020 | |
| Phathom Pharmaceuticals, INC. | $16.49 | 2024 | Voquezna |
| Idorsia Pharmaceuticals US INC | $13.44 | 2024 | Quviviq |
| Medtronic Vascular, INC. | $12.19 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.